Forum Financial Management LP Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Forum Financial Management LP grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,525 shares of the biopharmaceutical company's stock after buying an additional 4,867 shares during the period. Forum Financial Management LP's holdings in Gilead Sciences were worth $2,173,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Redwood Financial Network Corp increased its stake in Gilead Sciences by 4.0% in the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 98 shares during the last quarter. Nicolet Advisory Services LLC increased its stake in Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock valued at $322,000 after acquiring an additional 100 shares during the last quarter. Southland Equity Partners LLC increased its stake in Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after acquiring an additional 110 shares during the last quarter. Berkshire Bank boosted its position in Gilead Sciences by 3.4% during the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after buying an additional 111 shares during the period. Finally, CFO4Life Group LLC boosted its position in Gilead Sciences by 2.7% during the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock valued at $394,000 after buying an additional 112 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded up $1.72 on Tuesday, hitting $109.09. 7,928,580 shares of the company's stock were exchanged, compared to its average volume of 7,726,852. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The company has a 50-day simple moving average of $105.27 and a 200-day simple moving average of $100.46. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The stock has a market capitalization of $135.70 billion, a PE ratio of 294.84, a PEG ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the previous year, the firm posted ($1.32) EPS. The company's revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Analyst Upgrades and Downgrades

GILD has been the subject of several analyst reports. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Bank of America increased their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the transaction, the insider now owns 121,152 shares of the company's stock, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares in the company, valued at $19,977,938.37. This represents a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,929 shares of company stock worth $5,644,780. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.